Literature DB >> 6322709

Inhibition of theophylline clearance by cimetidine but not ranitidine.

J R Powell, J F Rogers, W A Wargin, R E Cross, F N Eshelman.   

Abstract

This study was designed to compare the effects of equivalent therapeutic doses of two H2 antagonists, cimetidine and ranitidine, on theophylline pharmacokinetics and to determine whether the previously described cimetidine-theophylline interaction is dose dependent. Twelve healthy adult men were given a 6-mg/kg intravenous aminophylline dose on four occasions. Subjects were randomly assigned four treatments: no treatment (control); cimetidine, 1,200 mg/day; cimetidine, 2,400 mg/day; and ranitidine, 300 mg/day. Cimetidine, 1,200 mg/day, significantly decreased theophylline clearance by 36% (range, 22% to 49%) and increased the mean elimination half-life from 5.7 hours (control) to 9.2 hours. A significant difference was not found between the two cimetidine dosages, indicating dose independence of the interaction over the dosage range studied. Ranitidine did not significantly alter theophylline pharmacokinetics. Theophylline plasma protein binding was not affected by any treatment. The relative effects of cimetidine and ranitidine on the elimination of cytochrome P-450 metabolized drugs such as theophylline indicate a useful property of ranitidine as compared with cimetidine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6322709

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  22 in total

Review 1.  Clinical relevance of cimetidine drug interactions.

Authors:  A F Shinn
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

Review 2.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

3.  The effect of raising gastric pH with ranitidine on the absorption and elimination of theophylline from a sustained-release theophylline tablet.

Authors:  C J Betlach; A B Straughn; M C Meyer; M Bialer; V I Vashi; P Liebermann; M A González
Journal:  Pharm Res       Date:  1991-12       Impact factor: 4.200

4.  Initial therapy for bacterial meningitis. Infectious Diseases and Immunization Committee, Canadian Paediatric Society.

Authors: 
Journal:  CMAJ       Date:  1990-02-15       Impact factor: 8.262

5.  Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.

Authors:  P K Honig; B K Gillespie
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

7.  Lack of an effect of nefazodone on the pharmacokinetics and pharmacodynamics of theophylline during concurrent administration in patients with chronic obstructive pulmonary disease.

Authors:  R C Dockens; D Rapoport; D Roberts; D S Greene; R H Barbhaiya
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335

8.  Health care for seniors: a new and burgeoning market.

Authors:  M Korcok
Journal:  CMAJ       Date:  1988-02-15       Impact factor: 8.262

9.  A house call to the big house.

Authors:  K Tompkins
Journal:  CMAJ       Date:  1989-04-15       Impact factor: 8.262

10.  The Sioux Lookout Program: "so many problems, so few physicians".

Authors:  E Michaels
Journal:  CMAJ       Date:  1989-10-15       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.